vs
Side-by-side financial comparison of HERTZ GLOBAL HOLDINGS, INC (HTZ) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.0B, roughly 1.2× HERTZ GLOBAL HOLDINGS, INC). Zoetis runs the higher net margin — 25.3% vs -9.6%, a 34.8% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -0.6%). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -1.3%).
Hertz Global Holdings, Inc., known as Hertz, is an American car rental company based in Estero, Florida. The company operates its namesake Hertz brand, along with the brands Dollar Rent A Car, Firefly Car Rental, and Thrifty Car Rental.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
HTZ vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $2.4B |
| Net Profit | $-194.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | -11.0% | 31.9% |
| Net Margin | -9.6% | 25.3% |
| Revenue YoY | -0.6% | 3.0% |
| Net Profit YoY | 59.5% | 3.8% |
| EPS (diluted) | $-0.46 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0B | $2.4B | ||
| Q3 25 | $2.5B | $2.4B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $1.8B | $2.2B | ||
| Q4 24 | $2.0B | $2.3B | ||
| Q3 24 | $2.6B | $2.4B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.1B | $2.2B |
| Q4 25 | $-194.0M | $603.0M | ||
| Q3 25 | $184.0M | $721.0M | ||
| Q2 25 | $-294.0M | $718.0M | ||
| Q1 25 | $-443.0M | $631.0M | ||
| Q4 24 | $-479.0M | $581.0M | ||
| Q3 24 | $-1.3B | $682.0M | ||
| Q2 24 | $-865.0M | $624.0M | ||
| Q1 24 | $-186.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | -11.0% | 31.9% | ||
| Q3 25 | 9.4% | 37.0% | ||
| Q2 25 | -14.5% | 36.7% | ||
| Q1 25 | -29.0% | 36.5% | ||
| Q4 24 | -27.6% | 31.6% | ||
| Q3 24 | -62.9% | 36.6% | ||
| Q2 24 | -20.1% | 33.0% | ||
| Q1 24 | -27.9% | 34.1% |
| Q4 25 | -9.6% | 25.3% | ||
| Q3 25 | 7.4% | 30.0% | ||
| Q2 25 | -13.5% | 29.2% | ||
| Q1 25 | -24.4% | 28.4% | ||
| Q4 24 | -23.5% | 25.1% | ||
| Q3 24 | -51.7% | 28.6% | ||
| Q2 24 | -36.8% | 26.4% | ||
| Q1 24 | -8.9% | 27.4% |
| Q4 25 | $-0.46 | $1.37 | ||
| Q3 25 | $0.42 | $1.63 | ||
| Q2 25 | $-0.95 | $1.61 | ||
| Q1 25 | $-1.44 | $1.41 | ||
| Q4 24 | $-1.57 | $1.29 | ||
| Q3 24 | $-4.34 | $1.50 | ||
| Q2 24 | $-2.82 | $1.37 | ||
| Q1 24 | $-0.61 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $565.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-459.0M | $3.3B |
| Total Assets | $22.3B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $565.0M | — | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $503.0M | $1.4B | ||
| Q1 25 | $626.0M | $1.7B | ||
| Q4 24 | $592.0M | $2.0B | ||
| Q3 24 | $501.0M | $1.7B | ||
| Q2 24 | $568.0M | $1.6B | ||
| Q1 24 | $465.0M | $2.0B |
| Q4 25 | $-459.0M | $3.3B | ||
| Q3 25 | $-317.0M | $5.4B | ||
| Q2 25 | $-504.0M | $5.0B | ||
| Q1 25 | $-262.0M | $4.7B | ||
| Q4 24 | $153.0M | $4.8B | ||
| Q3 24 | $681.0M | $5.2B | ||
| Q2 24 | $2.0B | $5.0B | ||
| Q1 24 | $2.8B | $5.1B |
| Q4 25 | $22.3B | $15.5B | ||
| Q3 25 | $23.0B | $15.2B | ||
| Q2 25 | $23.1B | $14.5B | ||
| Q1 25 | $22.0B | $14.1B | ||
| Q4 24 | $21.8B | $14.2B | ||
| Q3 24 | $23.0B | $14.4B | ||
| Q2 24 | $25.2B | $14.2B | ||
| Q1 24 | $24.3B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $193.0M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $193.0M | $893.0M | ||
| Q3 25 | $835.0M | $938.0M | ||
| Q2 25 | $346.0M | $486.0M | ||
| Q1 25 | $251.0M | $587.0M | ||
| Q4 24 | $414.0M | $905.0M | ||
| Q3 24 | $894.0M | $951.0M | ||
| Q2 24 | $546.0M | $502.0M | ||
| Q1 24 | $370.0M | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 4.54× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTZ
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
